AEGiS-Reuters: Abbott receives new FDA approval for Kaletra

Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.

Abbott receives new FDA approval for Kaletra

Reuters NewMedia - October 31, 2005

Abbott Laboratories Inc. said on Monday that U.S. regulators approved a new formulation of its HIV drug Kaletra that will allow patients to take fewer pills and will not need to be refrigerated.

Kaletra is the biggest-selling of a class of HIV drugs known as protease inhibitors. It was introduced in 2000. Adults taking Kaletra can now take the pill with or without food and the number of daily pills is reduced to four tablets from six a day.

051031
RE051033

Copyright © 2005 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .